8-K
filed February 6, 2023, 6:59 PM ET
ticker DRIO
CIK 0001533998
earnings
confidence high
sentiment positive
materiality 0.80
DarioHealth Corp. (DRIO): debt financing — DarioHealth Reports Preliminary FY2022 Revenue of $27.5M and Begins Loan Repayment
DarioHealth Corp.
2022-FY EPS reported
$2.54
revenue$27,656,000
- Preliminary full-year 2022 total revenue expected $27.5M, up from $20.5M in 2021.
- B2B channel grew to about 60% of revenue in 2022 versus 4% in 2021.
- Operating loss reduced by more than 50% compared to Q4 2021.
- Credit agreement with OrbiMed triggers monthly repayments of up to $518,500 starting January 2023.
- Cash and equivalents at end of 2022: $49.3 million.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
DarioHealth Corp. faced acceleration on credit facility of $25 million with OrbiMed Royalty and Credit Opportunities III, LP maturing June 9, 2027.
- Instrument
- credit facility
- Principal
- $25 million
- Counterparty
- OrbiMed Royalty and Credit Opportunities III, LP
- Maturity
- June 9, 2027
- Event
- acceleration
Exact text from the filing
the Company started repayment of the outstanding principal amount of the initial tranche of $25 million issued as part of the Loan Facility, together with a repayment premium and other fees in monthly installments of up to $518,500 beginning as of January 31, 2023, and continuing through the maturity date, or June 9, 2027.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DarioHealth Corp. reported the fiscal year ended December 31, 2022 results: revenue approximately $27.5 million.
- Period
- the fiscal year ended December 31, 2022
- Revenue
- approximately $27.5 million
- Result
- preliminary results
Exact text from the filing
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DarioHealth Corp. reported the fourth quarter ended December 31, 2022 results: revenue approximately $6.7 million.
- Period
- the fourth quarter ended December 31, 2022
- Revenue
- approximately $6.7 million
- Result
- preliminary results
Exact text from the filing
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.